The Motley Fool6d
Vertex Pharmaceuticals Just Won a Huge FDA Approval. Is the Biotech Stock a No-Brainer Buy?
The FDA recently approved Journavx for treating acute pain. This approval is tremendously important for Vertex Pharmaceuticals. The biotech company has also received other good news over the last ...
Yahoo Finance6d
Vertex Pharmaceuticals price target raised to $433 from $430 at Scotiabank
Scotiabank raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $433 from $430 and keeps a Sector Perform rating on the shares. Vertex’s suzetrigine, branded Journavx ...
Business Insider5d
Evercore ISI Keeps Their Buy Rating on Vertex Pharmaceuticals (VRTX)
Evercore ISI analyst Liisa Bayko maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) on January 31 and set a price target of $515.00. The company’s shares closed last ...
Pharmabiz6d
Vertex Pharmaceuticals’ suzetrigine gets US FDA approval for treatment of adults with moderate-to-severe acute pain
Vertex Pharmaceuticals Incorporated, an American biopharmaceutical company based in Boston, announced that the US Food and Drug Administration (FDA) has approved its Journavx (suzetrigine), an oral, ...
Morningstar5d
Vertex Pharmaceuticals Inc VRTX
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
South Boston Online18h
Important New VERTEX Painkiller Is Approved
By Rick Winterson  Vertex Pharmaceuticals is a worldwide biotechnology corporation. It was founded 35 years ago in Cambridge.  It has now established its global headquarters on Fan Pier in South ...